

DAFTAR PUSTAKA

- Ahmad, S, Aida, F, Hasnawi, H, Suryani, G. 2018. Pedoman Tatalaksana GBS, CIDP, MG dan Imunoterapi.. Edisi I. PERDOSSI.
- Akbayram, S., Doğan, M., Akgün, C., Peker, E., Sayın, R., Aktar, F., Bektaş, M.S. and Çaksen, H., 2011. Clinical features and prognosis with Guillain-Barre syndrome. *Annals of Indian Academy of Neurology*, 14(2):98.
- Alloush, T., Fahmy, N.A., Fouad, M.M., Albaroudy, H.O., Hamdy, M., Salem, H.H. 2019. Prediction of Outcome in Patients with Guillain-Barre Syndrome- An Egyptian Study. *Scientific Research*;10(3):00-00.
- Arsenijevic, M., Berisavac, I., Mladenovic, B., Stanarcevic, P., Jovanovic, D., Lavrnjic, D., et al. 2021. Rate of progression of Guillain-Barre syndrome is not associated with the short-term outcome of disease. *Ir J Med Sci*;190(1):257-361.
- Asbury, A.K., Cornblath, D.R. 1990. Assessment of current diagnostic criteria for Guillain- Barre syndrome. *Ann Neurol*, 27(Suppl.1):21-4.
- Ashrafi, M.R., Mohammadalipoor, A., Naeni, A.R., Amanat, M., Tavasoli, A.R., Heidari, M., et al. 2018. Clinical characteristics and electrodiagnostic features of Guillain-Barre Syndrome Among the Pediatric Population. *Journal of Child Neurology*.
- Badshah, M., Shabbir, G., Nabi, S.F. and Ahmed, D., 2018. Association of serum albumin levels and guillain barre syndrome (GBS) outcome. *Pakistan Journal of Neurological Sciences (PJNS)*, 13(2):1-6.
- Barnes, S.L., Herkes, G.K. 2020. Guillain-Barre syndrome clinical features, treatment choices and outcomes in an Australian cohort. *Internal Medicine Journal*; 50(12):1500-1504.
- Bento-Abreu, A., Velasco, A., Polo-Hernández, E., Pérez-Reyes, P.L., Tabernero, A. and Medina, J.M., 2008. Megalin is a receptor for albumin in astrocytes and is required for the synthesis of the neurotrophic factor oleic acid. *Journal of neurochemistry*, 106(3), pp.1149-1159.
- Bernsen, R.A., de Jager, A.E.J., Kuijer, W., van der Meche, F.G.A., Suurmeijer, T. 2009. Psychosocial dysfunction in the first year after Guillain-Barre Syndrome. *Muscle and Nerve*, Volume 41(4):533-539.
- Bhagat, S.K., Sidhant, S., Bhatta, M., Ghimire, A. and Shah, B., 2019. Clinical profile, functional outcome, and mortality of Guillain-Barre syndrome: a five-year tertiary care experience from Nepal. *Neurology Research International*, 2019.
- Bolukbasi, F., Ersen, G., Gunduz, A., Karaali-Savrun, F., Yazici, S., Uzun, N., et al. 2019. Guillain-Barre Syndrome and its variants: Clinical Course and Prognostic Factors. *Arch Neuropsychiatry*;56:71-74.
- Boostani, R., Ramezanzadeh, F., Saedi, M., Khobabandeh, M. 2019. A follow-up study on Guillain-Barre syndrome and validation of Brighton criteria. *Iranian Journal of Neurology*;18(2):64-9.
- Cabrera-Serrano, M., Fugate, J.E., Mandrekar, J. and Rabinstein, A.A., 2015. Impact of hyperglycemia in the outcome of patients with primary

- neuromuscular respiratory failure. *Neurocritical care*, 23, pp.103-107.
- Ceylan, M., Sonkaya, A.R. 2019. The investigation of guillain-barre syndrome and prognosis. *Annals of Medical Research*, 26(4):763-8.
- Chen, Y., Ma, F., Zhang, J., Chu, X. and Xu, Y., 2014. Population incidence of Guillain– Barré syndrome in parts of China: three large populations in Jiangsu province, 2008–2010. *European journal of neurology*; 21:124-129.
- Chevret, S., Hughes, R.A.C., Annane, D. 2017. Plasma exchange for Guillain-Barre Syndrome. *Cochrane Database of Systematic Review* 2017, 2:CD001798.
- Cutillo, G., Saariaho, A.H. and Meri, S., 2020. Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. *Cellular & Molecular Immunology*, 17(4): 313-322.
- Dahlan, M. S. 2018. *Membuat Proposal Penelitian Bidang Kedokteran dan Kesehatan*. Jakarta, Penerbit Salemba Medika.
- Dana, L., Warren, C.R. 2004. Guillain-Barre Syndrome. *Am Fam Physician*, 69(10):2405- 2410.
- Don, B.R., Kaysen, G. 2004. Serum albumin: relationship to inflammation and nutrition. *Seminars in Dialysis*, 17(6):432–437.
- Dubey, D., Kapotic, M., Freeman, M., Sawhney, A., Rojas, J.C., Warnack, W. and Vernino, S., 2016. Factors contributing to delay in diagnosis of Guillain-Barré syndrome and impact on clinical outcome. *Muscle & Nerve*, 53(3), pp.384-387.
- El-Khayat, N.M., Nada, M.A., El-Sayed, H.H., Nasr, M.A. 2018. Factors associated with prognosis of Guillain-Barre syndrome. *Clinical Psychology Cognitive Science*, 2(1): 29-31.
- El Soury, M., Fornasari, B.E., Carta, G., Zen, F., Haastert-Talini, K. and Ronchi, G., 2021. The role of dietary nutrients in peripheral nerve regeneration. *International Journal of Molecular Sciences*, 22(14):7417.
- Ethemoglu, O., Calik, M. 2018. Effect of serum inflammatory markers on the prognosis of adult and pediatric patients with Guillain-Barre Syndrome. *Neuropsychiatric Disease and Treatment*, 12:1255-1260.
- Fokkink, W.J.R., Walgaard, C., Kuitwaard, K., Tio-Gillen, A.P., van Doorn, P.A., Jacobs, B.C. 2016. Association of Albumin Levels with Outcom in Intravenous Immunoglobulin- treated GBS. *JAMA Neurology*; 27: E1-8.
- Frenzen, P.D. Economic cost of Guillain-Barre syndrome in the United States. 2009. *Neurology*, 71(1):21-7.
- Garg, M. 2017. Respiratory Involvement in Guillain-Barre Syndrome: The Uncharted Road to Recovery. *Journal of neurosciences in rural practice*, 8(3), 325–326.
- Gevorgyan, A., Sanossian, N., Beydoun, S.R. 2017. Guillain-Barre Syndrome Trend of Hospital Length of Stay, Complication Rate and Mortality Depending from Method of the Treatment: IVIg vs PLEX. *Neurology*; 16:88.
- Geyik, S., Bozkurt, H., Neyal, M., Yigiter, R., Kuzudisli, S., Kul, S. 2016. The Clinical Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Guillain-barre Syndrome Independent of Infection. *Medical Science and Discovery*, 3(8):305-11.
- Gong, Q., Liu, S., Xiao, Z., Fu, X. and Lu, Z., 2022. Elevated blood and cerebrospinal fluid glucose levels affect the severity and short-term prognosis of Guillain-Barré syndrome. *Neurological Research*, 44(2),

pp.121-127.

- Gonzalez-Suarez, I., Sanz-Gallego, I., de Rivera, F. J., Arpa, J. 2013. Guillain-Barre Syndrome: Natural history and prognostic factors: a retrospective review of 106 cases. *BMC Neurology*, 13:95.
- Gounden, V., Vashisht, R. and Jialal, I., 2021. Hypoalbuminemia. *StatPearls*.
- Gordon, P.H., Wilbourn, A.J. 2010. Early electrodiagnostic findings in Guillain-Barré syndrome. *Arch Neurology*, 58(6):913-7.
- Guan, Z., Shang, L., Zhang, W., Guo, Y., Xue, Y., Li, X., *et al.* 2017. A rating scale for the severity of Guillain-Barre syndrome. *Acta Neurology Scandivian*, 32:1-8.
- Gumusayla, S., Vural, G. 2019. The Predictive Value of Neutrophil-Lymphocyte Ratio in Disability of Guillain-Barre Syndrome. *Tip Dergisi*, 15:187-92.
- Gupta, D. and Lis, C.G., 2010. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. *Nutrition journal*, 9(1), pp.1-16.
- Hafsteinsdottir, B., Olafsson, E., Jakobsson, F. 2018. Incidence and outcome of Guillain-Barre Syndrome in Iceland: A population-based study. *Acta Neurol Scand*; 138(5):454-458.
- Harahap, I.S.K., Juananda, D., Nuroso, W.P. and Asmedi, A., 2021. P-PN005. The clinical characteristics and incidence of hypoalbuminemia in patients with guillain barré syndrome in Yogyakarta, Indonesia. *Clinical Neurophysiology*, 132(8), p.e108.
- Harm M. 2011. Inpatient Management of Guillain-Barre Syndrome. *Neurohospitalist*, 1(2):78- 84.
- Hashim, N.A., Mohamed, W.S. and Emad, E.M., 2020. Neutrophil-lymphocyte ratio and response to plasmapheresis in Guillain-Barré syndrome: a prospective observational study. *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, 56(1):1-6.
- Hiew, F.L., Winer, J.B. and Rajabally, Y.A., 2016. Hyponatraemia in Guillain-Barré syndrome revisited. *Acta Neurologica Scandinavica*, 133(4):295-301.
- Hossain, M. A., Hasan, M., Rahman, M. A., Baqui, M., Islam, M., & Hakim, M. (2020). Relationship of Glycemic Status with Disease Severity in Guillain-Barré Syndrome. *Journal of National Institute of Neurosciences Bangladesh*, 6(2), 96–100. <https://doi.org/10.3329/jninb.v6i2.50762>
- Hughes, R.A.C., Wijdicks, E.F.M., Barohn, R., Benson, E., Cornblath, D.R., Hahn, A.F., *et al.*, 2003. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*, 61(6):736-740.
- Hughes, R.A.C., Swan, A.V., Raphaël, J.C., Annane, D., van Koningsveld, R., van Doorn, P.A. 2007. Immunotherapy for Guillain-Barré syndrome: a systematic review. *Brain*, 130(9):2245–2257.
- Hughes, R.A., Brassington, R., Gunn, A.A. and van Doorn, P.A., 2016. Corticosteroids for Guillain-Barré syndrome. *Cochrane Database of Systematic Reviews*, (10).
- Huner, E.A., Dai, A.I., Demiryurek, A.T. 2018. Association of Neutrophil/Lymphocyte Ratio With Intravenous Immunoglobulin Treatment

- in Children With Guillain-Barre Syndrome. *Journal of Child Neurology*, 33(2):164-167.
- Ijaz, M., Khan, F., Khan, M.J., Khan, A., Ahmad, W., Ali, I. 2019. Outcomes of Guillain-Barre Syndrome Patients Admitted to Intensive Care Unit in Tertiary Care Hospital. *Dr. Sulainan Al Habib Medical Journal*;1(3):88-94.
- Inayah, N.H., Hasmono, D., Fidiana. 2015. Studi Penggunaan Kortikosteroid pada Pasien Guillain-Barre Syndrome (GBS) di RSUD Dr. Soetomo Surabaya. Universitas Airlangga.
- Jayanti, F.L., Setyaningsih, I., Harahap, I. S. K., 2020. Rasio Neutrofil Limfosit (RNL) Sebagai Prediktor Luaran Saat Discharge Pada Pasien Guillain-Barre Syndrome Dengan Terapi Plasma Exchange. Thesis. Universitas Gadjah Mada, Indonesia.
- Kalita, J., Misra, U.K., Goyal, G., Das, M. 2015. Guillain-Barre syndrome: sybtypes and predictors of outcome from India. *Journal of the Peripheral Nervous System*;19:36-43.
- Kalita, J., Ranjan, A., Misra, U.K. 2016. Outcome of Guillain-Barre syndrome patients with respiratory paralysis. *QJM: An International Journal of Medicine*;319-323.
- Kamil, K., Yazid, M.D., Idrus, R.B.H., Das, S., Kumar, J. 2019. Peripheral demyelinating Diseases: From Biology to Translational Medicine. *Frontiers in Neurology*, 10:87.
- Kenan, G., Kushnir, M., Leonov, Y., Ilgiyayev, E., Aroesty, R., Bhonkar, S., et al. 2020. Electrophysiological features and prognosis of Guillain-Barre syndrome in Israel: A single-center's 20 years' experience. *Journal of the Neurological Sciences*;417:117074.
- Khadilkar, S., Patel, B. 2017. Factors Affecting Outcome and the Role of Plasmapheresis in Guillain-Barre syndrome. *Journal of the Associations of Physicians of India*;65.
- Kishore, C.K., Vijayabhaskar, J., Vardhan, R.V., Sainareesh, V.V., Sriramnaveen, P., Sridhar, A.V.S.S.N., et al. 2014. Management of Guillain-Barre syndrome with plamapheresis or immunoglobulin: our experience from a tertiary care institute in South India. *Ren Fail*, 36(5):732-736.
- Korinthenberg, R., Trollmann, R., Felderhoff-Müser, U., Bernert, G., Hackenberg, A., Hufnagel, M., Pohl, M., Hahn, G., Mentzel, H.J., Sommer, C. and Lambeck, J., 2020. Diagnosis and treatment of Guillain-Barré syndrome in childhood and adolescence: an evidence-and consensus-based guideline. *European Journal of Paediatric Neurology*, 25:5-16.
- Krbec, M., Koudelková, K. and Duška, F., 2021. On acid-base effects of albumin. *Current Medical Research and Opinion*, 37(9):1515-1516.
- Kusumawati, A.D., Harahap, I.S.K. and Yudiyanta, Y., 2019. Low albumin and pretreatment severity score can predict the functional outcome of Guillain-Barré syndrome. *Journal of the Neurological Sciences*, 405:48.
- Lehmann, H.C., Hartung, H.P. 2011. Plasma exchange and intravenous immunoglobulins : Mechanism of action in immune-mediated neuropathies. *Journal of Neuroimmunology*, 231:61-69.
- Leonhard, S.E., Mandarakas, M.R., Gondim, F.A.A, Bateman, K., Ferreira, M.L.B.,

- Cornblath, D.R., et al. 2019. Diagnosis and management of Guillain-Barre Syndrome in ten steps. *Nature reviews neurology*, 15:671-683.
- Leung, J., Sejvar, J.J., Soares, J. and Lanzieri, T.M., 2020. Guillain-Barré syndrome and antecedent cytomegalovirus infection, USA 2009–2015. *Neurological Sciences*, 41(4): 885-891.
- LeVine, S.M., 2016. Albumin and multiple sclerosis. *BMC Neurology*, 16(1):1-12.
- Levison, L.S., Thomsen, R.W. and Andersen, H., 2022. Increased mortality following Guillain-Barré syndrome: A population-based cohort study. *European Journal of Neurology*, 29(4), pp.1145-1154.
- Liu, R.K., Chen, W.H., Hsieh, S.T. 2012. Plasma Exchange Versus Double Filtration Plasmapheresis in the Treatment of GBS. *Therapeutic Apheresis*;6(2):163-166.
- Lyu, R.K., Chen, W.H., Hsieh, S.T. 2012. Plasma Exchange Versus Double Filtration Plasmapheresis in the Treatment of GBS. *Therapeutic Apheresis*;6(2):163-166.
- Ma, L., Liu, S., Xiao, Z., Guan, J., Liu, Y., Yao, J., & Lu, Z. (2022). Comparison of the effects of different doses of Glucocorticoids on distinct subtypes of Guillain-Barré syndrome in Southern China. *BMC Neurology*, 22(1), 1–7. <https://doi.org/10.1186/s12883-022-02567-8>
- Mahecha, M.P., Ojeda, E., Vega, D.A., Sarmiento-Monroy, J.C., Anaya, J.M. 2017. Guillain- bare syndrome in Colombia: where do we stand now? *Immunology Research*, 65(1):72-81.
- Makris, K., Koniari, K., Spanou, L., Gialouri, E., Evodia, E. and Lelekis, M., 2016. Prognostic significance of serum albumin level changes in acute ischemic stroke: the role of biological and analytical variation. *Clinical Chemistry and Laboratory Medicine (CCLM)*, 54(1):143-150.
- Malek, E., Salameh, J. 2019. Guillain-Barre Syndrome. *Semin Neurol*; 39:589-595.
- Marshall, J.S., Warrington, R., Watson, W. and Kim, H.L., 2018. An introduction to immunology and immunopathology. *Allergy, Asthma & Clinical Immunology*, 14(2):1-10.
- Martic, V., Bozovic, I., Berisavac, I., Basta, I., Peric, S., Babic, M., et al. 2018. Three year Follow-Up Study in Patients with Guillain-Barre Syndrome. *Canadian Journal Neurology Science*;45:269-274.
- McLeod, B.C., 2012. Plasma and plasma derivatives in therapeutic plasmapheresis. *Transfusion*, 52:38S-44S.
- Meena, A.K., Khadilkar, S.V., Murthy, M.K. 2011. Treatment guidelines for Guillain-Barre Syndrome. *Annual Indian Academica Neurology*, 14(1):S73-S81.
- Mitoma, H. and Manto, M. eds., 2019. *Neuroimmune diseases: from cells to the living brain*. Springer.
- Moman, R. N., Gupta, N., Varacallo, M. (2022). Physiology, Albumin. In *StatPearls*. StatPearls Publishing.
- Motamed-Gorji, N., Matin, N., Tabatabaie, O., Pavone, P., Romano, C., Falsaperla, R, et al. 2017. Biological Drugs in Guillain-barre Syndrome: An Update. *Current Neuropharmacology*, 15(7):938-950.
- Nagappa, M., Rahul, W., Sinha, S., Bindu, P.S., Mathuranath, P.S., Rao, S.,

- Periyavan, S., Rao, G.U. and Taly, A.B., 2017. Guillain Barre Syndrome in the elderly: Experience from a tertiary-care hospital in India. *Journal of Clinical Neuroscience*, 46, pp.45-49.
- Nakano, Y., Kanda, T. 2016. Pathology of Guillain-Barre syndrome. *Clinical and Experimental Neuroimmunology*, 7: 312-319.
- Netto, A.B., Taly, A.B., Kulkarni, G.B., Rao, G.U.M. and Rao, S., 2011. Prognosis of patients with Guillain-Barré syndrome requiring mechanical ventilation. *Neurology India*, 59(5):707.
- Netto, A.B., Taly, A.B., Kulkarni, G.B., Rao, G.U.M. and Rao, S., 2017. Complications in mechanically ventilated patients of Guillain-Barre syndrome and their prognostic value. *Journal of Neurosciences in Rural Practice*, 8(01), pp.068-073.
- Nicholson, J.P., Wolmarans, M.R. & Park, G.R. 2000. The role of albumin in critical illness. *British Journal of Anaesthesia*, 85(4), pp.599–610.
- Nuroso, W.P., Setyaningsih, I., Dananjoyo, K. and Harahap, I.S.K., 2021. P-PN024. The profile of cerebrospinal fluid analysis in patients with Guillain-Barré Syndrome. *Clinical Neurophysiology*, 132(8):113.
- Nyati, K.K., Nyati, R. 2013. Role of *Campylobacter jejuni* Infection in the Pathogenesis of Guillain-Barre Syndrome: An Update. *BioMed Research International*, 13: 195.
- Ozdemir, H.H. 2016. Analysis of the albumin level, neutrophil-lymphocyte ratio, and platelet- lymphocyte ratio in Guillain-Barré syndrome. *Arquivos de Neuro-Psiquiatria*, 74(9):718–722.
- Paar, M., Rossmann, C., Nussold, C., Wagner, T., Schlagenhaut, A., Leschnik, B., Oetl, K., Koestenberger, M., Cvirn, G. and Hallström, S., 2017. Anticoagulant action of low, physiologic, and high albumin levels in whole blood. *PloS one*, 12(8), p.e0182997.
- Patel, P., Shah, D., Jani, C., Shah, J., Jani, R., Kelaiya, A., et al., 2022. Outcomes of patients presenting with Guillain-Barre Syndrome at a tertiary care center in India. *BMC neurology*, 22(1), pp.1-10.
- Park, S.H., Kim, N.H. 2016. Early Prediction Factors of Poor Outcome in Guillain-Barre Syndrome. *Soonchunhyang Medical Science*, 22(2): 79-82.
- Peric, S., Berisavac, I., Stojiljkovic Tamas, O., Rajic, S., Babic, M., Cvijanovic, M., Dominovic-Kovacevic, A., Basta, I., Beslac-Bumbasirevic, L. and Lavrnic, D., 2019. Guillain-Barré syndrome in the elderly. *Journal of the Peripheral Nervous System*, 21(2), pp.105-110.
- Piccione, E.A. 2013. Guillain-Barre Syndrome and Related Disorders. *Neuromuscular Disorders in Clinical Practice*, 25:573-603.
- Pithadia, A.B. and Kakadia, N., 2010. Guillain-Barré syndrome (GBS). *Pharmacological reports*, 62(2):pp.220-232.
- Prajapati, K.D., Sharma, S.S. and Roy, N., 2011. Current perspectives on potential role of albumin in neuroprotection. *Reviews in the neurosciences*, 22(3): 355-363.
- Pritchard, J. 2011. Guillain-Barre Syndrome. *Clinical Medicine*, 10(4):399-401.
- Rajabally, Y.A., Uncini, A. 2012. Outcome and its predictors in Guillain-Barre syndrome. *Journal Neurosurgery Psychiatry*;83:711-718.

- Rath, J., Zulehner, G., Schober, B., Grisold, A., Krenn, M., Cetin, H. and Zimprich, F., 2021. Cerebrospinal fluid analysis in Guillain–Barré syndrome: value of albumin quotients. *Journal of Neurology*, 268(9):3294–3300.
- Rumalla, K., Reddy, A.Y., Letchuman, V., Mittal, M.K. 2017. Hyponatremia in Guillain-Baree Syndrome. *Journal of Cilinical Neuromuscular Disease*;18(4)
- Safa, A., Azimi, T., Sayad, A., Taheri, M., & Ghafouri-Fard, S. (2021). A review of the role of genetic factors in Guillain-Barré syndrome. *Journal of molecular neuroscience : MN*, 71(5): 902–920.
- Safri, A.Y., Avisenna, R., Indrawati, L.A., Octaviana, F., Hakim, M. 2018. Guillain-Barre Syndrome outcome at Cipto Mangunkusumo Hospital Jakarta Indonesia. *Clinical Neurophysiology*, 129(1):e153-e154.
- Sejvar, J.J., Baughman, A.L., Wise, M. 2011. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. *Neuroepidemiology*, 36:123e33.
- Shangab, M., Al Kaynani, M. 2020. Clinical Course and Predictors of Poor Functional Outcome in Guillain-Barre Syndrome. A Retrospective Study. *Dubai Med J*;3:93-98.
- Shah, M.A., Khan, M., Hussain, A., Latif, M., Rahim, I.U. and Manzoor, Z., Guillain-Barre Syndrome, Clinical Features at Presentation and Outcome. *Pain*, 62, pp.73-43.
- Shahrizaila, N., Lehmann, H. C., & Kuwabara, S. (2021). Guillain-Barré syndrome. *Lancet (London, England)*, 397(10280): 1214–1228.
- Shang, P., Zhu, M., Wang, Y., Zheng, X., Wu, X., Zhu, J., et al., 2021. Axonal variants of Guillain–Barré syndrome: an update. *Journal of Neurology*, 268(7), pp.2402-2419.
- Siddiqui, S.H., Siddiqui, T.H., Babar, M.U., Khoja, A., Khan, S. 2018. Outcomes of patients with Guillain Barre Syndrome – Experience from a tertiary care hospital of a developing Asian country and review of regional literature. *Journal of Cilinical Neuroscience*, 1:58-64.
- Siddiqui, S.H., Siddiqui, T.H., Babar, M.U., Khoja, A. and Khan, S., 2019. Outcomes of patients with Guillain Barre Syndrome–Experience from a tertiary care hospital of a developing Asian country and review of regional literature. *Journal of Clinical Neuroscience*, 62, pp.195-198.
- Sipilä, J.O., Kauko, T. and Soilu-Hänninen, M., 2017. Admission sodium level and prognosis in adult Guillain–Barré syndrome. *International Journal of Neuroscience*, 127(4), pp.344-349.
- Soeters, P.B., Wolfe, R.R. and Shenkin, A., 2019. Hypoalbuminemia: pathogenesis and clinical significance. *Journal of Parenteral and Enteral Nutrition*, 43(2), pp.181-193.
- Srinivas, D., Sriganesh, K., Chakrabarti, D. and Venkateswaran, P., 2021. Effect of Therapeutic Plasma Exchange on Plasma Constituents in Neurointensive Care Unit Patients: A Retrospective Study. *Journal of Neuroanaesthesiology and Critical Care*, 8(03):197-202.
- Su, Z., Chen, Z., Xiang, Y., Wang, B., Huang, Y., Yang, D., Li, X., et al., 2017. Low serum levels of uric acid and albumin in patients with Guillain–Barre syndrome. *Medicine*, No 96:15.

- Suarez, I.G., Gallego, I.S., de Rivera, F.J.R., Azpa, J. 2017. Guillain-Barre Syndrome: Natural history and prognostic factor: a retrospective review of 106 cases. 2017. *BMC Neurology* No. 13:95.
- Sung, E.J., Kim, D.Y., Chang, M.C., Ko, E.J. 2016. Prediction of Functional Outcome in Axonal Guillain-Barre Syndrome. *Ann Rehab Med*, 40(3):481-488.
- Tabernero, A., Granda, B., Medina, A., Sánchez-Abarca, L.I., Lavado, E. and Medina, J.M., 2002. Albumin promotes neuronal survival by increasing the synthesis and release of glutamate. *Journal of neurochemistry*, 81(4): 881-891.
- Tan. C.Y., Razali. S.N.O., Goh. K.J., Shahrizaila. N. 2019. The utility of Guillain-Barre syndrome prognostic models in Malaysian patients. *International Society of Travel Medicine*;24:168-173.
- Taverna, M., Marie, A.L., Mira, J.P. and Guidet, B., 2013. Specific antioxidant properties of human serum albumin. *Annals of intensive care*, 3(1):1-7.
- Tian, J., Cao, C., Li, T., Zhang, K, Li, P., Liu, Y., et al. 2019. Electrophysiological Subtypes and Prognostic Factors of Guillain-Barre Syndrome in Northern China. *Frontiers in Neurology*;10:714.
- Tiwari, I., Alam, A., Kanta, C., Koonwar, S., Garg, R.K., Pandey, S., Jain, A. and Kumar, R., 2022. A novel prognostic system based on clinical and laboratory parameters for childhood Guillain-Barre syndrome. *Acta Neurologica Belgica*, 122(5), pp.1237-1245.
- Tunc, A. 2019. Early predictors of functional disability in Guillain-Barre Syndrome. *Acta Neurologica Belgica*.119(4):555-559.
- Tothova, C.S., Nagy, O. and Kovac, G., 2014. Acute phase proteins and their use in the diagnosis of diseases in ruminants: a review. *Veterinárni medicína*; 59:4.
- Van den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B.C., van Doorn, P.A. 2014. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. *Natural Review Neurology* 10:469-82.
- Van Koningsveld, R., Steyerberg, E.W., Hughes, R.A., Swan, A.V., van Doorn, P.A. and Jacobs, B.C., 2007. A clinical prognostic scoring system for Guillain-Barré syndrome. *The Lancet Neurology*, 6(7):589-594.
- Van Leeuwen, N., Lingsma, H.F., Vanrolleghem, A.M., Sturkenboom, M.C., van Doorn, P.A., Steyerberg, E.W. and Jacobs, B.C., 2016. Hospital admissions, transfers and costs of Guillain-Barré syndrome. *PloS one*, 11(2):e0143837.
- Verboon, C., van Doorn, P.A., Jacobs, B.C. 2017. Treatment dilemmas in Guillain-Barre Syndrome. *Journal Neurology Neurosurgery Psychiatry*, 88:346-352.
- Walgaard, C., Lingsma, H.F., Ruts, L. 2010. Prediction of respiratory insufficiency in Guillain-Barre syndrome. *Annual Neurology*, 67:781-787.
- Walgaard, C., Lingsma, H.F., Ruts, L. 2011. Early recognition of poor prognosis in Guillain-Barre syndrome. *Annual Neurology*, 76:968-975.
- Walling, A.D., Dickson, G. 2013. Guillain-Barre Syndrome. *Am Fam Physician*, 87(3):191- 197.
- Wang, Y., Liu, J. 2015. Hyponatremia is a predictor for poor outcome in Guillain-Barre syndrome. *Neurological Research*;37(4):347-351.

- Wang, Y., Sun, S., Zhu, J., Cui, L., Zhang, H.L. 2015. Biomarkers of Guillain-Barré syndrome: some recent progress, more still to be explored. *Mediators Inflammation*, 54:1065-71.
- Wen, H.J., 2018. Acute bilateral vision deficit as the initial symptom in Guillain-Barre syndrome: A case report. *Experimental and Therapeutic Medicine*, 16(3):2712-2716.
- Wen, P., Wang, L., Liu, H., Gong, L., Ji, H., & Wu, H. 2021. Risk factors for the severity of Guillain - Barré syndrome and predictors of short - term prognosis of severe Guillain - Barré syndrome. *Scientific Reports*, 1–9.
- Weng, Y.Y., Yang, D.H., Qian, M.Z., Wei, M.M., Yin, F., Li, J., Li, X., Chen, Y., Ding, Z.N., He, Y.B. and Zhang, X., 2016. Low serum albumin concentrations are associated with disease severity in patients with myasthenia gravis. *Medicine*, 95(39).
- World Health Organization, 2016. Assessment and management of Guillain-Barré syndrome in the context of Zika virus infection: interim guidance update (No. WHO/ZIKV/MOC/16.4 Rev. 1). *World Health Organization*.
- Xie, K.H., Liu, L.L., Su, C.Y., Huang, X.F., Wu, B.X., Liu, R.N., et al., 2020. Low Antioxidant Status of Serum Uric Acid, Bilirubin, Albumin, and Creatinine in Patients With Benign Paroxysmal Positional Vertigo. *Frontiers in neurology*, p.1435.
- Yamagishi, Y., Suzuki, H., Sonoo, M., Kuwabara, S., Yokota, T., Nomura, K., et al. 2017. Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study. *Journal of Peripher Nerve System*, 22:433–9.
- Zhang, G., Li, Q., Zhang, R., Wei, Z., Wang, J., Qin, X. 2015. *Subtypes and Prognosis of Guillain-Barre Syndrome in Southwest China. PLoS ONE* 10(7): e0133520.
- Zhang, J., Song, X.J., Hou, H.Q., Tan, G. J., Bian, G. Y., Li, B., et al. 2016. Electrophysiological subtypes and long term prognosis of Guillain-Barre syndrome. *National Medical Journal of China*;96:25.
- Zhang, Y., Zhao, Y., Wang, Y. 2019. Prognostic factors of Guillain-Barre syndrome: a 111- case retrospective review. *Chinese Neurosurgical Journal*, 4:14.